|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | |
| **Online supplementary table 3: Antiplatelet and anticoagulant protocol used in the 3 patients with thrombotic events during the procedure** | | | | |
|  | Type FD | Antiplatelet and anticoagulant protocol | Additional therapy | Platelet function test and result |
| Case #1 | Surpass | At start of procedure ASA 500mg i.v. and ticagrelor 180mg via nasogastric tube. Heparinization 3500 IU during the procedure. | Shortly after placement of the flow diverter thrombus formation occurred for which 10mg abciximab was administered. At end of procedure no thrombus was visible. | No |
| Case #2 | FRED | ASA 500mg i.v. and prasugrel 60mg per os during the procedure prior to flow diverter deployment. Heparinization 8000 IU during the procedure. | The FD was occluded a few minutes after placement. An abciximab 20mg bolus was given immediately, and the thrombus mostly disappeared within 15 minutes. Abciximab 10mg infusion was given thereafter. | Yes, Verify Now: PRU < 230 |
| Case #3 | FRED | Prasugrel 60 mg loading dose orally half an hour before intervention, Heparinization 7000 IU during the procedure. | The stent was occluded immediately. An abciximab bolus of 16mg was administered directly. The flow diverter opened well with abciximab. After the bolus, abciximab was continued as infusion and the total dose was 30mg. | Yes, Verify Now: PRU < 230 |
| **ASA = acetylsalicylic acid; FD = flow diverter; PRU = P2Y12 reaction units; TE = thromboembolic** | | | | |